Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AZD1390 and Radiation Therapy in Pediatric High Grade Glioma
NCT06894979Phase 1Active, not recruiting
- Sponsor
- Children's Oncology Group
- Start
- Jun 2025
- Primary completion
- Mar 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of azd1390 in glioma, diffuse midline glioma (DMG) and diffuse intrinsic pontine glioma (DIPG), sponsored by Children's Oncology Group. Primary endpoints: Maximum Tolerated Dose or Recommended Phase 2 Dose at 75 days, Incidence of Adverse Events at 5 years and 5 more. Started Jun 2025; status: active, not recruiting.
02
Drugs
azd1390
03
Conditions
gliomadiffuse midline glioma (DMG)diffuse intrinsic pontine glioma (DIPG)
Beyond the preview
Go deeper on NCT06894979.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06894979.